FI  Boxer Capital

https://www.boxercap.com/





     Office Locations:

11682 El Camino Real, Suite 320
San Diego, CA 92130
Phone: 858-400-3115

 

Stages:

  • Early


 

Industries:

  • Life Sciences & Healthcare

  •  

    Description:

    Boxer Capital, LLC, is a private investment fund based in San Diego, California that invents and invests in biotechnology drug development across multiple therapeutic indications. Founded by the life sciences team at Family Office,Tavistock Group (see profile) in 2005, the firm maintains a concentrated portfolio of public and private companies.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or Southern California Database subscription.
    Aaron Davis Co-Founder and Chief Executive Officer
    Christopher Fuglesang Co-Founder and Managing Director
    Dominik Naczynski Senior VP
    Norman Zhou Senior VP
    Sid Subramony VP

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      11/02/2021


      Shoreline Biosciences


      CA


      $140,000,000


      Venture


      04/13/2021


      Theseus Pharmaceuticals


      MA


      $100,000,000


      Series B


      02/24/2021


      Vividion Therapeutics


      CA


      $135,000,000


      Series C


      02/16/2021


      Centessa Pharmaceuticals


      MA


      $250,000,000


      Series A


      02/11/2021


      Day One Biopharmaceuticals


      CA


      $130,000,000


      Series B


     

    Portfolio companies include:

     

    Recent News: